Una revisión crítica del estado del arte de CRISPR-Cas9 ante las adversidades:una herramienta multidisciplinar de plena vigencia

  1. Ekain Payán Ellacuria 1
  1. 1 Universidad del País Vasco/Euskal Herriko Unibertsitatea
    info

    Universidad del País Vasco/Euskal Herriko Unibertsitatea

    Lejona, España

    ROR https://ror.org/000xsnr85

Journal:
IUS ET SCIENTIA: Revista electrónica de Derecho y Ciencia

ISSN: 2444-8478

Year of publication: 2018

Issue Title: TRANSHUMANISMO Y DERECHO

Volume: 4

Issue: 1

Pages: 132-145

Type: Article

DOI: 10.12795/IETSCIENTIA.2018.I01.08 DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: IUS ET SCIENTIA: Revista electrónica de Derecho y Ciencia

Sustainable development goals

Abstract

Since its discovery, the gene edition, with CRISPR-Cas9 at its head, has become one of the great biological hopes for eradicating some of the most serious diseases that plague human beings. Obviously, due to the interest aroused by its application, together with its undeniable ethical and legal implications, as well as economic and commercial interests, numerous investigations have increased in recent months, some of which have been able to call into question the promising future that this tool was initially predicted to have. In this regard, the one carried out by Stanford University (USA) is noteworthy, according to which the patients presented immune adaptations (antibodies and T lymphocytes) against the Cas9 protein, which operates as a molecular scissor. The second is an article written in an impact scientific journal that tried to refute, in an inconclusive way, the unexpected gene mutations that the use of CRISPR-Cas9 would produce. At the same time, it has been known that, following in the footsteps of China and USA, Europe will be attending the first clinical trial with CRISPR-Cas9 in 2018 as a treatment for a rare disease (beta thalassemia), which will make it possible to verify its safety and efficacy. The aim of this article is to highlight the full growth and relentless advance of technology, given that there are real solutions to the various problems that arise, but that require responsible research and an increase in both funding and clinical trials.

Bibliographic References

  • BOTHMER, A. / MAEDER, M. L. / REYON, D. / WILSON, C. J. / COTTA-RAMUSINO, C. / FERNÁNDEZ, C. A. / MARCO, E. / BARRERA, L. A. / JAYARAM, H. / ALBRIGHT, C. F. / COX, G. F. / CHURCH, G. M. / MYER, V. E., “The experimental design and data interpretation in “Unexpected mutations after CRISPR-Cas9 editing in vivo” by Schaefer et al. are insufficient to support the conclusions drawn by the authors”. Disponible online. [Última consulta: 11 de mayo de 2018].
  • BURGIO, G., “Should we be worried about CRISPR/Cas9 off target effects?”, Medium, June 2017. Disponible online. [Última consulta: 11 de mayo de 2018].
  • CHARLESWORTH, C. T. / DESHPANDE, P. S. / DEVER, D. P. / DJENE, B. / GÓMEZ-OSPINA, N. / MANTRI, S. / PAVEL-DINU, M. / CAMARENA, J. / WEINBERG, K. I. / PORTEUS, M. H., “Identification of Pre-Existing Adaptive Inmmunity to Cas9 Proteins in Humans”, BioRxiv. The prepintserver for biology, January 2018. Disponible online. [Última consulta: 11 de mayo de 2018].
  • DE MIGUEL BERIAIN, I. / ARMAZA ARMAZA, E., “Un análisis ético de las nuevas tecnologías de edición genética: el CRISPR-Cas9 a debate”, Anales de la Cátedra Francisco Suárez, Vol. 52, 2018. Disponible online. [Última consulta: 11 de mayo de 2018].
  • GASKELL, G. / BARD, I. / ALLANSDOTTIR, A. / VIEIRA DA CUNHA, R. / EDUARD,P. / HAMPEL, J. / HILDT, E. / HOFMAIER, C. / KRONBERGER, N. / LAURSEN, S. / MEIJKNECHT, A. / NORDAL, S. / QUINTANILHA, A. / REVUELTA, G. / SALADIÉ, N. / SANDOR, J. / BORLIDO SANTOS, J. / SEYRINGER, S. / SINGH, L. / SOMSEN, H. / TOONDERS, W. / TORGERSEN, H. / TORRE, V. / VARJU, M. / ZWART, H., “Public views on gene editing and its uses”, Nature Biotechnology, No.35, November 2017. Disponible online. [Última consulta: 11 de mayo de 2018].
  • IYER, V. / BOROVIAK, K. / THOMAS, M. / DOE, B. / RYDER, E. / ADAMS, D., “No unexpected CRISPR-Cas9 off target activity revealed by trio sequencing of gene-edited mice”, BioRxiv. The prepint server for biology, February 2018. Disponible online. [Última consulta: 11 de mayo de 2018].
  • IYER, V. / SHEN, B. / ZHANG, W. / HODGKINS, A. / KEANE, T. / HUANG, X. / SKARNES, W. C., “Off-target mutations are rare in Cas9-modified mice”, Nature Methods, No. 12, May 2015. Disponible online. [Última consulta: 11 de mayo de 2018].
  • JINEK, M. / CHYLINSKI, K. / FONFARA, I. / HAUER, M. / DOUDNA, J.A. / CHARPENTIER, E., “A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity, Science, Vol. 337, August 2012.
  • JOSEPH, A., “Genome-editing companies play down CRISPR paper, as concerns drive down shares”, STAT-Reporting from the frontiers of health and medicine (Biotech), January 8, 2018. Disponible online. [Última consulta: 11 de mayo de 2018]. LACADENA, J.-R., “Genética yHumanismo. Edición genómica: ciencia y ética”, Revista Iberoamericana de Bioética, Núm. 3, 2017.
  • LAREAU, C. / CLEMENT, K. / HSU, J. Y. / PATTANAYAK, V. / JOUNG, J. K. / ARYEE, M. J. / PINELLO, A., “Unexpected mutations after CRISPR-Cas9 editing in vivo” are most likely pre-existing sequence variants and not nuclease-induced mutations”, BioRxiv. The prepint server for biology, July 2017. Disponible online. [Última consulta: 11 de mayo de 2018].
  • MOJICA, F. J. M. / JUEZ, G. / RODRÍGUEZ-VALERA, F., “Transcription at different salinities of Haloferax mediterranei sequences adjacent to partially modified Pstl sites”, Molecular Microbiology, No. 3, Vol. 9, August 1993.
  • SCHAEFER, K. A. / WU, W.-H. / COLGAN, D. F. / TSANG, S. H. / BASSUK, A. G. / MAHAJAN, V. B., “Unexpected mutations after CRISPR-Cas9 editing in vivo”, Nature Methods, No. 14, May 2017. Disponible online. [Última consulta: 11 de mayo de 2018].
  • SCHAEFER, K. A. / DARBRO, B. W. / COLGAN, D. F. / TSANG, S. H. / BASSUK, A. G. / MAHAJAN, V. B., “Corrigendum and follow-up: Whole genome sequencing of multiple CRISPR-edited mouse lines suggests no excess mutations”, BioRxiv. The prepintserver for biology, June 2017. Disponible online. [Última consulta: 11 de mayo de 2018].
  • SERUGGIA, D. / FERNÁNDEZ, A. / CANTERO, M. / PELCZAR, P. / MONTOLIU, L., “Functional validation of mouse tyrosinase non-coding regulatory DNA elements by CRISPR-Cas9 mediated mutagenesis”, Nucleic AcidsResearch,Vol.43,April2015. Disponible online. [Última consulta: 11 de mayo de 2018].
  • WAGNER, D. L. / AMANI, L. / WENDERING, D. J. / REINKE, P. / VOLK, H.-D. / SCHMUECK-HENNERESSE, M., “High prevalence of S. pyogenes Cas9-specific T cell sensitization within the adult human population -A balanced effector/regulatory T cell response”, The prepint server for biology, April 2018. Disponible online. [Última consulta: 11 de mayo de 2018].
  • ZETSCHE, B. / GOOTENBERG, J. S. / ABUDAYYEH, O. O. / SLAYMAKER, I. M. / MAKAROVA, K. S. / ESSELETZBICHLER, P. / VOLZ, S. E. / JOUNG, J. / VAN DER OOST, J. / REGEV, A. / KOONIN, E. V. / ZHANG, F., “Cpf Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System”, Cell, Vol. 163, October 2015. Disponible online. [Última consulta: 11 de mayo de 2018].
Data source: Dialnet